{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:20:23Z","timestamp":1791829223557,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s40266-012-0014-3","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T15:49:13Z","timestamp":1355759353000},"page":"863-869","source":"Crossref","is-referenced-by-count":117,"title":["Diagnosing and Managing Postherpetic Neuralgia"],"prefix":"10.1007","volume":"29","author":[{"given":"Srinivas","family":"Nalamachu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Morley-Forster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,5]]},"reference":[{"issue":"3 Suppl","key":"14_CR1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/erv.10.30","volume":"9","author":"RW Johnson","year":"2010","unstructured":"Johnson RW. Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines. 2010;9(3 Suppl):21\u20136.","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"14_CR2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4065\/84.3.274","volume":"84","author":"P Sampathkumar","year":"2009","unstructured":"Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009;84(3):274\u201380.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"14_CR3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3810\/pgm.2011.09.2469","volume":"123","author":"CE Argoff","year":"2011","unstructured":"Argoff CE. Review of current guidelines on the care of postherpetic neuralgia. Postgrad Med. 2011;123(5):134\u201342.","journal-title":"Postgrad Med"},{"issue":"11","key":"14_CR4","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","volume":"82","author":"BP Yawn","year":"2007","unstructured":"Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341\u20139.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"14_CR5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00005792-198209000-00003","volume":"61","author":"MW Ragozzino","year":"1982","unstructured":"Ragozzino MW, Melton LJ 3rd, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore). 1982;61(5):310\u20136.","journal-title":"Medicine (Baltimore)"},{"key":"14_CR6","first-page":"CD007795","volume":"3","author":"N Chen","year":"2011","unstructured":"Chen N, Li Q, Zhang Y, et al. Vaccination for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2011;3:CD007795.","journal-title":"Cochrane Database Syst Rev"},{"key":"14_CR7","unstructured":"Zostavax\u00ae (zoster vaccine live): US prescribing information. Whitehouse Station, NJ: Merck & Co., Inc., 2011."},{"issue":"Suppl 2","key":"14_CR8","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1086\/522159","volume":"197","author":"MN Oxman","year":"2008","unstructured":"Oxman MN, Levin MJ, Shingles Prevention Study Group. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis. 2008;197(Suppl 2):S228\u201336.","journal-title":"J Infect Dis"},{"issue":"9","key":"14_CR9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-152-9-201005040-00004","volume":"152","author":"MS Simberkoff","year":"2010","unstructured":"Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med. 2010;152(9):545\u201354.","journal-title":"Ann Intern Med"},{"issue":"7","key":"14_CR10","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","volume":"54","author":"KE Schmader","year":"2012","unstructured":"Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359\u00a0years. Clin Infect Dis. 2012;54(7):922\u20138.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"14_CR11","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1086\/514342","volume":"44","author":"MB Rothberg","year":"2007","unstructured":"Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007;44(10):1280\u20138.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"14_CR12","first-page":"64","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2011;60(2):64.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"14_CR13","doi-asserted-by":"crossref","first-page":"1113-e88","DOI":"10.1111\/j.1468-1331.2010.02999.x","volume":"17","author":"N Attal","year":"2010","unstructured":"Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.","journal-title":"Eur J Neurol"},{"issue":"6","key":"14_CR14","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1212\/01.WNL.0000140708.62856.72","volume":"63","author":"RM Dubinsky","year":"2004","unstructured":"Dubinsky RM, Kabbani H, El-Chami Z, et al. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;63(6):959\u201365.","journal-title":"Neurology"},{"issue":"2","key":"14_CR15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jpain.2006.06.005","volume":"8","author":"RH Dworkin","year":"2007","unstructured":"Dworkin RH, Jensen MP, Gammaitoni AR, et al. Symptom profiles differ in patients with neuropathic versus non-neuropathic pain. J Pain. 2007;8(2):118\u201326.","journal-title":"J Pain"},{"key":"14_CR16","unstructured":"Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings. London, UK: National Institute for Health and Clinical Excellence; 2011 February. Report No.: NICE clinical guideline 59."},{"key":"14_CR17","doi-asserted-by":"crossref","unstructured":"Li Q, Chen N, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009; (2):CD006866.","DOI":"10.1002\/14651858.CD006866.pub2"},{"issue":"3","key":"14_CR18","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0003-9993(98)90016-8","volume":"79","author":"SM Chen","year":"1998","unstructured":"Chen SM, Chen JT, Kuan TS, et al. Myofascial trigger points in intercostal muscles secondary to herpes zoster infection of the intercostal nerve. Arch Phys Med Rehabil. 1998;79(3):336\u20138.","journal-title":"Arch Phys Med Rehabil"},{"key":"14_CR19","unstructured":"McElveen WA. Postherpetic neuralgia differential diagnoses. http:\/\/emedicine.medscape.com\/article\/1143066-overview . Accessed 11 May 2011."},{"issue":"1\u20132","key":"14_CR20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pain.2009.06.001","volume":"146","author":"R Baron","year":"2009","unstructured":"Baron R, Tolle TR, Gockel U, et al. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: differences in demographic data and sensory symptoms. Pain. 2009;146(1\u20132):34\u201340.","journal-title":"Pain"},{"issue":"3","key":"14_CR21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2007.08.033","volume":"132","author":"RH Dworkin","year":"2007","unstructured":"Dworkin RH, O\u2019Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237\u201351.","journal-title":"Pain"},{"issue":"1","key":"14_CR22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1155\/2007\/730785","volume":"12","author":"DE Moulin","year":"2007","unstructured":"Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain\u2014consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007;12(1):13\u201321.","journal-title":"Pain Res Manag"},{"key":"14_CR23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-540-79090-7_1","volume":"194","author":"R Baron","year":"2009","unstructured":"Baron R. Neuropathic pain: a clinical perspective. Handb Exp Pharmacol. 2009;194:3\u201330.","journal-title":"Handb Exp Pharmacol"},{"issue":"3","key":"14_CR24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pain.2005.08.013","volume":"118","author":"NB Finnerup","year":"2005","unstructured":"Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118(3):289\u2013305.","journal-title":"Pain"},{"issue":"12","key":"14_CR25","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/jnnp.2008.144964","volume":"81","author":"T Saarto","year":"2010","unstructured":"Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry. 2010;81(12):1372\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"14_CR26","doi-asserted-by":"crossref","unstructured":"Moore RA, Wiffen PJ, Derry S, et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011; (3):CD007938.","DOI":"10.1002\/14651858.CD007938.pub2"},{"key":"14_CR27","doi-asserted-by":"crossref","unstructured":"Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009; (3):CD007076.","DOI":"10.1002\/14651858.CD007076.pub2"},{"issue":"6","key":"14_CR28","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-2710.2009.01144.x","volume":"35","author":"TG Tzellos","year":"2010","unstructured":"Tzellos TG, Toulis KA, Goulis DG, et al. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis. J Clin Pharm Ther. 2010;35(6):639\u201356.","journal-title":"J Clin Pharm Ther"},{"issue":"7","key":"14_CR29","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1185\/03007990903047880","volume":"25","author":"R Baron","year":"2009","unstructured":"Baron R, Mayoral V, Leijon G, et al. 5\u00a0% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin. 2009;25(7):1663\u201376.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"14_CR30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00044011-200929040-00002","volume":"29","author":"R Baron","year":"2009","unstructured":"Baron R, Mayoral V, Leijon G, et al. Efficacy and safety of 5\u00a0% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. Clin Drug Investig. 2009;29(4):231\u201341.","journal-title":"Clin Drug Investig"},{"issue":"6","key":"14_CR31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00044011-200929060-00003","volume":"29","author":"A Binder","year":"2009","unstructured":"Binder A, Bruxelle J, Rogers P, et al. Topical 5\u00a0% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig. 2009;29(6):393\u2013408.","journal-title":"Clin Drug Investig"},{"issue":"7","key":"14_CR32","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1185\/03007995.2010.483675","volume":"26","author":"S Rehm","year":"2010","unstructured":"Rehm S, Binder A, Baron R. Post-herpetic neuralgia: 5\u00a0% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study. Curr Med Res Opin. 2010;26(7):1607\u201319.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"14_CR33","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1185\/03007990902901368","volume":"25","author":"G Hans","year":"2009","unstructured":"Hans G, Sabatowski R, Binder A, et al. Efficacy and tolerability of a 5\u00a0% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study. Curr Med Res Opin. 2009;25(5):1295\u2013305.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"14_CR34","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1371\/journal.pmed.0020164","volume":"2","author":"K Hempenstall","year":"2005","unstructured":"Hempenstall K, Nurmikko TJ, Johnson RW, et al. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med. 2005;2(7):e164.","journal-title":"PLoS Med"},{"issue":"5","key":"14_CR35","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/jps.10133","volume":"91","author":"BJ Campbell","year":"2002","unstructured":"Campbell BJ, Rowbotham M, Davies PS, et al. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci. 2002;91(5):1343\u201350.","journal-title":"J Pharm Sci"},{"issue":"2","key":"14_CR36","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1345\/aph.1A185","volume":"36","author":"AR Gammaitoni","year":"2002","unstructured":"Gammaitoni AR, Davis MW. Pharmacokinetics and tolerability of lidocaine patch 5\u00a0% with extended dosing. Ann Pharmacother. 2002;36(2):236\u201340.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"14_CR37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/0091270002239817","volume":"43","author":"AR Gammaitoni","year":"2003","unstructured":"Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5\u00a0%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol. 2003;43(2):111\u20137.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"14_CR38","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1212\/WNL.59.7.1015","volume":"59","author":"SN Raja","year":"2002","unstructured":"Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2002;59(7):1015\u201321.","journal-title":"Neurology"},{"issue":"1\u20132","key":"14_CR39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0304-3959(99)00007-X","volume":"81","author":"M Nolano","year":"1999","unstructured":"Nolano M, Simone DA, Wendelschafer-Crabb G, et al. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain. 1999;81(1\u20132):135\u201345.","journal-title":"Pain"},{"issue":"4","key":"14_CR40","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1526-4637.2009.00793.x","volume":"11","author":"MM Backonja","year":"2010","unstructured":"Backonja MM, Malan TP, Vanhove GF, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med. 2010;11(4):600\u20138.","journal-title":"Pain Med"},{"issue":"2 Pt 1","key":"14_CR41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0190-9622(89)70171-7","volume":"21","author":"JE Bernstein","year":"1989","unstructured":"Bernstein JE, Korman NJ, Bickers DR, et al. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol. 1989;21(2 Pt 1):265\u201370.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"14_CR42","first-page":"510","volume":"15","author":"CP Watson","year":"1993","unstructured":"Watson CP, Tyler KL, Bickers DR, et al. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther. 1993;15(3):510\u201326.","journal-title":"Clin Ther"},{"issue":"7","key":"14_CR43","first-page":"702","volume":"10","author":"C Noto","year":"2009","unstructured":"Noto C, Pappagallo M, Szallasi A. NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain. Curr Opin Investig Drugs. 2009;10(7):702\u201310.","journal-title":"Curr Opin Investig Drugs"},{"issue":"2","key":"14_CR44","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/AJP.0b013e318227403d","volume":"28","author":"GA Irving","year":"2012","unstructured":"Irving GA, Backonja M, Rauck R, et al. NGX-4010, a capsaicin 8\u00a0% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia. Clin J Pain. 2012;28(2):101\u20137.","journal-title":"Clin J Pain"},{"key":"14_CR45","unstructured":"Qutenza\u00ae (capsaicin 8\u00a0% patch): US prescribing information. San Mateo, CA: NeurogesX, Inc., 2009."},{"issue":"12","key":"14_CR46","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2165\/11596280-000000000-00000","volume":"25","author":"Y Vorobeychik","year":"2011","unstructured":"Vorobeychik Y, Gordin V, Mao J, et al. Combination therapy for neuropathic pain: a review of current evidence. CNS Drugs. 2011;25(12):1023\u201334.","journal-title":"CNS Drugs"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-012-0014-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T00:28:11Z","timestamp":1562459291000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-012-0014-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,5]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["14"],"URL":"https:\/\/doi.org\/10.1007\/s40266-012-0014-3","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,5]]}}}